ALK and neoplasm: We remain steadfast in our efforts to exploit ALK as a tumor-restricted antigen by developing an ADC with a humanized ALK-directed antibody with cross-species reactivity to decrease immunogenicity risk, and with conjugation to a cytotoxic payload with maximal potency and a physically stable linker.